Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
暂无分享,去创建一个
S. Fulda | K. Debatin | S Fulda | K-M Debatin
[1] J Downward,et al. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain , 2002, Cell Death and Differentiation.
[2] Robert L Moritz,et al. Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.
[3] S. Srinivasula,et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[4] Martin Schuler,et al. Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.
[5] Emad S. Alnemri,et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis , 2001, Nature.
[6] G. Kroemer,et al. The Central Executioner of Apoptosis: Multiple Connections between Protease Activation and Mitochondria in Fas/APO-1/CD95- and Ceramide-induced Apoptosis , 1997, The Journal of experimental medicine.
[7] John Calvin Reed,et al. Conversion of Bcl-2 from Protector to Killer by Interaction with Nuclear Orphan Receptor Nur77/TR3 , 2004, Cell.
[8] H. Pehamberger,et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice , 1998, Nature Medicine.
[9] D. Green,et al. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. , 1998, Molecular cell.
[10] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[11] Michael Karin,et al. NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.
[12] Petr Pancoska,et al. p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.
[13] A. Giaccia,et al. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. , 2002, Cancer cell.
[14] Shaomeng Wang,et al. Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. , 2005, Bioorganic & medicinal chemistry letters.
[15] Xiaodong Wang,et al. Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.
[16] M. Peter,et al. Activation of Mitochondria and Release of Mitochondrial Apoptogenic Factors by Betulinic Acid* , 1998, The Journal of Biological Chemistry.
[17] S. B. Bratton,et al. Recruitment, activation and retention of caspases‐9 and ‐3 by Apaf‐1 apoptosome and associated XIAP complexes , 2001, The EMBO journal.
[18] B. Zhivotovsky,et al. Caspase-2 Permeabilizes the Outer Mitochondrial Membrane and Disrupts the Binding of Cytochrome c to Anionic Phospholipids* , 2004, Journal of Biological Chemistry.
[19] H. Koeppen,et al. Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4 , 2001, The Journal of Immunology.
[20] Alexei Degterev,et al. A decade of caspases , 2003, Oncogene.
[21] Tak W. Mak,et al. Pathways of apoptotic and non-apoptotic death in tumour cells , 2004, Nature Reviews Cancer.
[22] G. Kroemer,et al. AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis , 2004, Oncogene.
[23] R. Rich,et al. Requirement of Both the Second and Third BIR Domains for the Relief of X-linked Inhibitor of Apoptosis Protein (XIAP)-mediated Caspase Inhibition by Smac* , 2003, Journal of Biological Chemistry.
[24] S. Lowe,et al. Suppression of tumorigenesis by the p53 target PUMA. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[25] S. Srinivasula,et al. Caspase-2 Induces Apoptosis by Releasing Proapoptotic Proteins from Mitochondria* , 2002, The Journal of Biological Chemistry.
[26] W. Deppert,et al. Transcription-independent pro-apoptotic functions of p53. , 2005, Current opinion in cell biology.
[27] Clemencia Pinilla,et al. Cellular, Biochemical, and Genetic Analysis of Mechanism of Small Molecule IAP Inhibitors* , 2004, Journal of Biological Chemistry.
[28] Shaomeng Wang,et al. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. , 2004, Journal of medicinal chemistry.
[29] A. Fornace,et al. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[30] A. Österborg,et al. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D , 2001, Leukemia.
[31] M. Peter,et al. Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.
[32] Gerolama Condorelli,et al. PED mediates AKT-dependent chemoresistance in human breast cancer cells. , 2005, Cancer research.
[33] S. Fulda,et al. Targeting apoptosis pathways in cancer therapy. , 2004, Current cancer drug targets.
[34] E. White,et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. , 2005, Cancer cell.
[35] M. Hengartner. The biochemistry of apoptosis , 2000, Nature.
[36] J. Skepper,et al. Paclitaxel Affects Cytosolic Calcium Signals by Opening the Mitochondrial Permeability Transition Pore* , 2002, The Journal of Biological Chemistry.
[37] G. Kroemer,et al. Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death? , 2002, Journal of Cell Science.
[38] P. Krammer,et al. FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis , 2001, Molecular and Cellular Biology.
[39] R. Stahel,et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. , 2001, Journal of the National Cancer Institute.
[40] S. Lowe,et al. Generation and Characterization of Smac/DIABLO-Deficient Mice , 2002, Molecular and Cellular Biology.
[41] A. Ashkenazi,et al. Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.
[42] S. Fulda,et al. Apoptosis in hematological disorders. , 2003, Seminars in cancer biology.
[43] W. El-Deiry,et al. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.
[44] S. Strom,et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.
[45] M. Nau,et al. Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines , 2000, Breast Cancer Research and Treatment.
[46] T. McDonnell,et al. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.
[47] Joanna K. Sax,et al. BID regulation by p53 contributes to chemosensitivity , 2002, Nature Cell Biology.
[48] M. Gleave,et al. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells , 2005, Molecular Cancer Therapeutics.
[49] F. Oriente,et al. Omi/HtrA2 Promotes Cell Death by Binding and Degrading the Anti-apoptotic Protein ped/pea-15* , 2004, Journal of Biological Chemistry.
[50] H. Pehamberger,et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy , 2000, The Lancet.
[51] S. Fulda,et al. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells , 1997, Leukemia.
[52] K. Debatin,et al. Mutation analysis of the apoptotic “death‐receptors” and the adaptors TRADD and FADD/MORT‐1 in osteosarcoma tumor samples and osteosarcoma cell lines , 2004, International journal of cancer.
[53] R. Davis,et al. Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.
[54] Y. Tsujimoto,et al. Involvement of Histone H1.2 in Apoptosis Induced by DNA Double-Strand Breaks , 2003, Cell.
[55] T L Chenevert,et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[56] P. Krammer,et al. CD95's deadly mission in the immune system , 2000, Nature.
[57] B. Zhivotovsky,et al. Distinct Pathways for Stimulation of Cytochrome cRelease by Etoposide* , 2000, The Journal of Biological Chemistry.
[58] Ximena Opitz-Araya,et al. Requirement for Caspase-2 in Stress-Induced Apoptosis Before Mitochondrial Permeabilization , 2002, Science.
[59] T. Taniguchi,et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.
[60] P. Vandenabeele,et al. Toxic proteins released from mitochondria in cell death , 2004, Oncogene.
[61] P. Nowell,et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.
[62] D. Israeli,et al. p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.
[63] S. Korsmeyer,et al. Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.
[64] W. May,et al. Phosphorylation of Bcl2 and regulation of apoptosis , 2001, Leukemia.
[65] K. Kinzler,et al. PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.
[66] H. Nakayama,et al. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. , 2001, Molecular cell.
[67] Dajun Yang,et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. , 2004 .
[68] S. S. Strom,et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.
[69] Y. Hamada,et al. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95‐mediated apoptosis by down‐regulating FLIP‐L expression , 2000, International journal of cancer.
[70] P. Marks,et al. Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.
[71] Z. Wang,et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.
[72] D. Green,et al. The Pathophysiology of Mitochondrial Cell Death , 2004, Science.
[73] P. Galle,et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.
[74] D. Trisciuoglio,et al. Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Gene–Amplified Breast Cancer Cells , 2004, Clinical Cancer Research.
[75] H. Tagawa,et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.
[76] S. Fulda,et al. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.
[77] D. Vaux,et al. Mammalian mitochondrial IAP binding proteins. , 2003, Biochemical and biophysical research communications.
[78] Shaomeng Wang,et al. Structure-based design of potent, conformationally constrained Smac mimetics. , 2004, Journal of the American Chemical Society.
[79] W L Allen,et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death , 2006, Oncogene.
[80] Mark H Ellisman,et al. Disruption of Mitochondrial Function during Apoptosis Is Mediated by Caspase Cleavage of the p75 Subunit of Complex I of the Electron Transport Chain , 2004, Cell.
[81] I. Bechmann,et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) , 2000, The Lancet.
[82] D. Goeddel,et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. , 1998, Science.
[83] I. Weissman,et al. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. , 1998, Immunity.
[84] W. el-Deiry,et al. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling , 2001, Cell Death and Differentiation.
[85] D. Botstein,et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.
[86] W. El-Deiry,et al. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. , 2001, Experimental cell research.
[87] E. Solary,et al. Cisplatin-Induced CD95 Redistribution into Membrane Lipid Rafts of HT29 Human Colon Cancer Cells , 2004, Cancer Research.
[88] Sten Orrenius,et al. Caspase-2 Acts Upstream of Mitochondria to Promote Cytochromec Release during Etoposide-induced Apoptosis* , 2002, The Journal of Biological Chemistry.
[89] E. Solary,et al. STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. , 1999, Biochemical and biophysical research communications.
[90] Geng Wu,et al. Structural basis of IAP recognition by Smac/DIABLO , 2000, Nature.
[91] G. Kroemer,et al. Chemotherapy: targeting the mitochondrial cell death pathway , 2002, Oncogene.
[92] Xiaodong Wang,et al. Structural and biochemical basis of apoptotic activation by Smac/DIABLO , 2000, Nature.
[93] Jean-Claude Martinou,et al. Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli , 2002, The Journal of cell biology.
[94] S. Fulda,et al. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system , 1998, International journal of cancer.
[95] B. Zhivotovsky,et al. Processed caspase‐2 can induce mitochondria‐mediated apoptosis independently of its enzymatic activity , 2004, EMBO Reports.
[96] M. Weller,et al. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release , 2001, Oncogene.
[97] J. Tschopp,et al. The PIDDosome, a Protein Complex Implicated in Activation of Caspase-2 in Response to Genotoxic Stress , 2004, Science.
[98] G. Kroemer,et al. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis , 2001, Oncogene.
[99] B. Zhivotovsky,et al. Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide. , 2004, Experimental cell research.
[100] T. Mak,et al. Specific Ablation of the Apoptotic Functions of Cytochrome c Reveals a Differential Requirement for Cytochrome c and Apaf-1 in Apoptosis , 2005, Cell.
[101] S. Srinivasula,et al. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity , 2002, Cell Death and Differentiation.
[102] M. Peter,et al. Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. , 1995, The EMBO journal.
[103] G. Wilson,et al. Apoptosis Genes and Resistance to Cancer Therapy: What Does the Experimental and Clinical Data Tell Us? , 2003, Cancer biology & therapy.
[104] Martin Schuler,et al. Cytochrome C Maintains Mitochondrial Transmembrane Potential and Atp Generation after Outer Mitochondrial Membrane Permeabilization during the Apoptotic Process , 2001, The Journal of cell biology.
[105] J. Downward,et al. The Serine Protease Omi/HtrA2 Regulates Apoptosis by Binding XIAP through a Reaper-like Motif* , 2002, The Journal of Biological Chemistry.
[106] A. Strasser. The role of BH3-only proteins in the immune system , 2005, Nature Reviews Immunology.
[107] Michael Weller,et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.
[108] Seamus J. Martin,et al. Regulation of Apoptotic Protease Activating Factor-1 Oligomerization and Apoptosis by the WD-40 Repeat Region* , 1999, The Journal of Biological Chemistry.
[109] T. Hashikawa,et al. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways , 2004, Cell Death and Differentiation.
[110] Jian Zhao,et al. Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo , 2006, Cancer Gene Therapy.
[111] W. El-Deiry,et al. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[112] Rachel L. Allen,et al. Defying death after DNA damage , 2000, Nature.
[113] F. Cotter. Unraveling biologic therapy for Bcl-2-expressing malignancies. , 2004, Seminars in oncology.
[114] S. Cory,et al. The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.
[115] Clemencia Pinilla,et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. , 2004, Cancer cell.
[116] L. Attardi,et al. The role of apoptosis in cancer development and treatment response , 2005, Nature Reviews Cancer.
[117] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[118] José Luis de la Pompa,et al. Differential Requirement for Caspase 9 in Apoptotic Pathways In Vivo , 1998, Cell.
[119] P. Bouillet,et al. Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[120] L. Berczi,et al. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma , 2003, Cell Death and Differentiation.
[121] D. Lawrence,et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.
[122] C. Belka,et al. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL , 2001, Oncogene.
[123] Xiaodong Wang,et al. A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death , 2004, Science.
[124] F. Talos,et al. Mitochondrially targeted p53 has tumor suppressor activities in vivo. , 2005, Cancer research.
[125] Gail Walker,et al. Apaf-1 Oligomerizes into Biologically Active ∼700-kDa and Inactive ∼1.4-MDa Apoptosome Complexes* , 2000, The Journal of Biological Chemistry.
[126] J. Beckmann,et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. , 1998, Immunity.
[127] J C Reed,et al. Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.
[128] T. Mak,et al. Apaf1 Is Required for Mitochondrial Pathways of Apoptosis and Brain Development , 1998, Cell.
[129] G. Gores,et al. Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ * , 2002, The Journal of Biological Chemistry.
[130] F. Alt,et al. Proapoptotic BID is required for myeloid homeostasis and tumor suppression. , 2003, Genes & development.
[131] I. Herr,et al. Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.
[132] J. Norris,et al. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[133] I. McNeish,et al. Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway. , 2003, Experimental cell research.
[134] W. El-Deiry,et al. Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis* , 2004, Journal of Biological Chemistry.
[135] P. Krammer,et al. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.
[136] Xiaodong Wang,et al. Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.
[137] S. Korsmeyer,et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.
[138] G. Kroemer,et al. Mitochondrion as a novel target of anticancer chemotherapy. , 2000, Journal of the National Cancer Institute.
[139] A. Ashkenazi,et al. Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.
[140] H. Friess,et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract , 1999, Oncogene.
[141] John Calvin Reed,et al. Dysregulation of apoptosis genes in hematopoietic malignancies , 2002, Oncogene.
[142] Emad S. Alnemri,et al. Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi , 2002, Nature Structural Biology.
[143] R. Coombes,et al. FoxO3a Transcriptional Regulation of Bim Controls Apoptosis in Paclitaxel-treated Breast Cancer Cell Lines* , 2003, Journal of Biological Chemistry.
[144] A. Strasser,et al. BH3-only proteins - evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. , 2002, Journal of cell science.
[145] T. Sumi,et al. Molecular-dynamics study of liquid mercury in the density region between metal and nonmetal , 1999 .
[146] S. Nagata. Apoptotic DNA fragmentation. , 2000, Experimental cell research.
[147] J. Houghton,et al. Thymineless death in colon carcinoma cells is mediated via fas signaling. , 1997, Proceedings of the National Academy of Sciences of the United States of America.